louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03485560: Revitalization of Damaged Skin Due to Chronic Skin Diseases
Official title: Revitalization of Damaged Sking Due to Chronic Skin Diseases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Chronic Eczema
Psoriasis
Atopic Dermatitis
Keywords: chronic skin disease
psoriasis
Eczema
atopic dermatitis
Lead sponsor: Ace Cells Lab Limited
Sponsor class: INDUSTRY
First posted: 2018-04-02
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture of natural peptides and herbs. the main aim is to restore the normal skin appearance for the patient and control the episodes of flare.

Detailed description: Psoriasis is a chronic, immune mediated (type 2 and type 17) chronic skin disease. The production of the immune proteins that leads to continuous inflammatory mediated process. The result of chronic inflammation is they hyper keratotic layer of skin which gets attacks of atopic dermatitis leading to symptoms of itching, pruritis and in situ bleeding.

ACE CSD, with the multiple factors that mediates the immune response and control the protein receptors, in addition to the multiple regeneration peptides that are specifically extracted from healthy skin of newly born sheep; in addition to multiple Chinese herbs that contains different anabolic factors was tested to be able to regenerate the damaged skin and locally modulate the immunity reactions so the skin can regenerate fully to replace the damaged skin with normal healthy skin.

Eligibility criteria: Inclusion Criteria:

* Chronic skin condition lasts for more than 1 year.
* tried traditional treatment with limited or without effect.
* not on steroids for at least 6 weeks.

Exclusion Criteria:

* patients on steroid.
* patients intolerable to protein or allergic to proteins
* during pregnancy or lactation

Primary outcomes:
measure: Regeneration of the damaged skin lesion
timeFrame: 6 - 9 months
Secondary outcomes:
measure: Flare control
timeFrame: 1-3 months
Other outcomes:
Locations:
city: Belgrade
country: Serbia
facility: ACE cells Lab Europe Doo
city: Nottingham
country: United Kingdom
facility: ACE Cells Lab Limited
state: Nottinghamshire
Study officials:
affiliation: ACE cells Lab europe DOO
name: Dr. Diana Diana, MSc Dermatology
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00171860: A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Official title: A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hypereosinophilic Syndrome
Keywords: Hypereosinophilic syndrome
Imatinib
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-09-15
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objectives of the study are:

1. Evaluation of the safety profile of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome resistant or refractory to, or intolerant of, prednisone, hydroxyurea or interferon-alpha, or untreated patients carrying the Fip1L1-PDGFRA fusion protein.
2. Evaluation of the efficacy of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome
3. Analysis of patient's blood samples for the detection of activated kinases.


Eligibility criteria: Inclusion Criteria:

Idiopathic hypereosinophilic syndromes are included provided they belong to one of the following categories:

1. previously treated and showing documented resistance or refractoriness to, or intolerance of, prednisone, hydroxyurea or interferon-alpha.
2. not previously treated but with documented Fip1L1-PDGFRA fusion protein

Exclusion Criteria:

* Other diseases associated with hypereosinophilia
* Serum creatinine, serum bilirubin, AST, ALT more than twice the upper normal limit.
* ECOG performance status \>3

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Rate of complete and partial response and relapse
Secondary outcomes:
measure: Bone Marrow Analysis
measure: Peripheral blood detection of Fip1L1-PDGFRA tyrosine kinase
measure: Disease-Related Symptoms and Signs
measure: Organ Involvement
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT00453960: Genistein and Endometrial Hyperplasia
Official title: Effect of Genistein on Endometrial Hyperplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Endometrial Hyperplasia
Keywords: Endometrial hyperplasia
Genistein
Isoflavones
dysfunctional uterine bleeding
Lead sponsor: University of Messina
Sponsor class: OTHER
First posted: 2007-03-29
Enrollment: 59
Sex: FEMALE
Minimum age (years): 44
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to verify the anti-estrogenic activity of Genistein, on the "non atypical endometrial hyperplasia", in premenopausal women.

Detailed description: Although isoflavones alone (example: Genistein) have weak estrogenic effects on endometrial stromal and glandular cells, it was demonstrated, in several research efforts, that in the presence of E2 they act as antiestrogens.

Considered that endometrial hyperplasia is due to strong and extended estrogenic stimulation, not offset by a proportionate amount of progesterone, we suppose that genistein could be therapeutic in these cases inducing a decrease of the hyperplasia and a change from the proliferative to a secretory phase of the endometrium.

Eligibility criteria: Inclusion Criteria:

* Premenopausal women
* Age \> = 44 years
* Dysfunctional uterine bleeding
* No treatment with other hormonal drugs (estrogen, progesterone)
* No local or general pathology negatively influenced by administration of genistein or progesterone
* No intrauterine pathologies (polyps, myomas)
* A "non atypical endometrial hyperplasia", confirmed by hysteroscopy with biopsy and histological examination

Exclusion Criteria:

* All the other conditions

Primary outcomes:
measure: Recovery from endometrial hyperplasia
timeFrame: 3-6 months
Secondary outcomes:
measure: Differential expression of ER-a and ER-b in endometrial specimens
timeFrame: 6 months
Other outcomes:
Locations:
city: Messina
country: Italy
facility: Menopause Centre, Department of Gynecology and Obstetrics, Policlinico Universitario "G.Martino"
Study officials:
affiliation: menopause centre
name: Rosario D'Anna, prof.
role: STUDY_DIRECTOR
References:
citation: Kayisli UA, Aksu CA, Berkkanoglu M, Arici A. Estrogenicity of isoflavones on human endometrial stromal and glandular cells. J Clin Endocrinol Metab. 2002 Dec;87(12):5539-44. doi: 10.1210/jc.2002-020716.
Clinical trial NCT00559260: Evaluation of Cardiorespiratory Events in Subjects Undergoing an Upper and/or Lower Endoscopy Under Current Sedation Practices
Official title: Evaluation of Cardiorespiratory Events in Subjects Undergoing an Upper and/or Lower Endoscopy Under Current Sedation Practices While Being Passively Monitored
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sedation for Non-Emergent Upper and/or Lower Endoscopy
Lead sponsor: Ethicon Endo-Surgery
Sponsor class: INDUSTRY
First posted: 2007-11-16
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: This is a 300 subject prospective study to assess cardiorespiratory events associated with current practice sedation (150 subjects; opioid + benzodiazepine) versus anesthesia provider sedation (150 subjects; propofol) for upper and/or lower endoscopy.


Eligibility criteria: Inclusion Criteria:adult

* (\>=18 years),ASA I-III, non-emergent upper and/or lower endoscopy

Exclusion Criteria:

* Emergent indications for upper and/or lower endoscopy (i.e., acute hemorrhage, cholangitis)
* Baseline respiratory rate of \< 6 breaths per minute
* Baseline hypotension (systolic blood pressure \< 90 mm Hg)
* Baseline arterial oxygen saturation \< 90% on room air
* Baseline bradycardia: heart rate \< 50 beats per minute
* Baseline tachycardia: heart rate \> 110 beats per minute
* Allergy or inability to tolerate any of the sedatives or analgesics to be administered during the procedure
* Inability to squeeze the Automated Responsiveness Test hand piece (last 50 subjects only)
* Significant hearing impairment
* Actively abusing alcohol, opioids, benzodiazapines or sedatives, or other drugs
* Are considered tolerant to opioids, benzodiazapines and/or other sedatives through prescription.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: Oklahoma Foundation for Digestive Research
state: Oklahoma
Study officials:
affiliation: Oklahoma Foundation for Digestive Research
name: Philip Miner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03074760: A Study of Acequias Contamination & Association of Infectious Diseases in Peru
Official title: A Study of Acequias Contamination & Association of Infectious Diseases in Peru
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Water-Related Diseases
Lead sponsor: BioRed LLC
Sponsor class: OTHER
First posted: 2017-03-09
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: There is no study population in phase I as it is focused on the districts and their corresponding acequias. Phase II of this study will include participants 18 years of age or older who consent to participate and are from the following districts: Eten, Pomalca, Pimentel, Patapo, Pucala, Santa Rosa, Reque, Monsefu and Sana.

Brief summary: A major water supply utilized in the Lambayeque region are acequias. Acequias are irrigation canals that are utilized by the agriculture industry for the cultivation of consumables. Utilization of contaminated water to irrigate consumables can lead to foodborne illnesses. Contamination studies on the acequias in the Lambayeque region have not been performed to date. The purpose of this study is to test contamination of acequias in 9 districts in Lambayeque and determine if a difference in infection rates exists in districts with contaminated acequias vs. districts without contaminated acequias for the following diseases: H. pylori, Adenovirus, Rotavirus.


Eligibility criteria: Inclusion Criteria:

* Currently reside in one of the following districts: Eten, Pomalca, Pimentel, Patapo, Pucala, Santa Rosa, Reque, Monsefu and Sana
* 18 years of age or older
* Consent to participate

Exclusion Criteria:

* Currently taking antiviral or antimicrobial medication

Primary outcomes:
measure: Contamination of acequias
timeFrame: March 20th - April 1st
Secondary outcomes:
measure: Proportion of population with infections
timeFrame: March 20th - May 1st
Other outcomes:
Locations:
city: Patapo
country: Peru
facility: BioRed
state: Lambayeque
city: Pimentel
country: Peru
facility: BioRed
state: Lambayeque
city: Pomalca
country: Peru
facility: BioRed
state: Lambayeque
city: Pucala
country: Peru
facility: BioRed
state: Lambayeque
city: Tuman
country: Peru
facility: BioRed
state: Lambayeque
Study officials:
affiliation: Campbell University
name: Robert E Goode
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00282360: Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease
Official title: Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Type II Diabetes Mellitus
Keywords: coronary artery disease
diabetes mellitus
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2006-01-26
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with coronary artery disease have an abnormal cardiac metabolism. The hypothesis of this study is that shifting cardiac metabolism from free fatty acids to glucose will improve myocardial ischemia

Detailed description: The present study will evaluate the effect of free fatty acid inhibition with Trimetazidine on silent myocardial ischemia and total ischemic burden in coronary artery disease patients with type II diabetes.

Patients will undergo ambulatory ECG monitoring at baseline and will be randomized to receive on top of thei standard anti-anginal therapy trimetazidine or placebo for 6 months. Patients will repeat the ambulatory ECG monitoring at the end of the study

Eligibility criteria: Inclusion Criteria:

coronary artery disease type II diabetes mellitus -

Exclusion Criteria:

unstable coronary artery syndromes impaired liver and kidney function

-

Primary outcomes:
measure: total ischemic burden
measure: silent ischemia
Secondary outcomes:
measure: symptomatic myocardial ischemia
Other outcomes:
Locations:
Study officials:
affiliation: H San Raffaele EUR
name: Giuseppe Marazzi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06957860: Septal Bone Expansion Using Osseodensification Versus Piezoelectric Implant Site Preparation
Official title: Septal Bone Expansion Using Osseodensification Versus Piezoelectric Implant Site Preparation for Immediate Implant Placement in Mandibular Molars [Randomized Clinical Trial]
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Implant
Osseodensification
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-05-05
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: : Implant placement in the inter radicular septum is usually considered the best option for an immediate molar implant, not only in terms of correct 3D positioning, but also regarding implant survival, Osseodensification was shown to enhance implant primary stability, due to the compaction auto-grafting and the associated spring-back effect. Piezoelectric implant site preparation (PISP) has been proposed as an alternative technique to improve surgical control, safety, and bone healing response Aim of the work: To evaluate and compare stability changes using insertion torque values (ITV) and Implant Stability Quotient values (ISQ) for immediately placed implants in molar septum using Osseodensification technique and Piezoelectric implant site preparation (PISP) technique.


Eligibility criteria: Inclusion Criteria:

* Adult patients with hopeless mandibular molar teeth in the posterior region in need of implant placement .
* A fully intact facial bone wall at the extraction site.
* Systemically healthy, received no head and neck radiation for cancer treatment.
* Absence of periapical pathologies or suppuration at the time of installing the implants.
* Septal bone after atraumatic extraction not less than 3 mm.

Exclusion Criteria:

* Systemic conditions that would prevent successful healing or implant osseointegration; examples are uncontrolled Diabetes Mellitus, metabolic bone disorders, autoimmune diseases, or Bisphosphonate therapy.
* Heavy smoker patients.
* Presence of preapical bone loss related to extracted tooth.
* Patient is not indicated for immediate implant placement

Primary outcomes:
measure: Change in implant stability
timeFrame: Baseline and 3 months
Secondary outcomes:
measure: Change in bone density
timeFrame: Baseline and 3 months
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University
Study officials:
References:
Clinical trial NCT01789060: p-AKT Expression on Clinical Outcomes in Malignant Lymphoma
Official title: The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malignant Lymphoma
P13K-AKT Pathway Deregulation
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2013-02-11
Enrollment: 262
Sex: ALL
Minimum age (years): 17
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with malignant lymphoma who are treated in a tertiary hospital in Korea (Samsung Medical Center)

Brief summary: PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Detailed description: Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B \[PKB\]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Eligibility criteria: Inclusion Criteria:

1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.

Exclusion Criteria:

1. Primary central nervous system lymphoma was excluded in this study

Primary outcomes:
measure: Difference of overall survival according to p-AKT status in malignant lymphoma
timeFrame: study entry
Secondary outcomes:
measure: Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)
timeFrame: study entry
Other outcomes:
measure: Subgroup analysis of overall survival according to International Prognostic Index risk groups
timeFrame: study entry
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Won Seog Kim, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hong JY, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. Ann Oncol. 2014 Jan;25(1):182-8. doi: 10.1093/annonc/mdt530.
Clinical trial NCT04144660: "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Official title: "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiogenic Shock
Peripartum Cardiomyopathy
Complication, Pregnancy
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
Collaborators: name: Medical College of Wisconsin
First posted: 2019-10-30
Enrollment: 5
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women treated with ECMO while pregnant or immediately postpartum (within six months).

Brief summary: The goal of this study is to describe the use of ECMO (Extracorporeal Membrane Oxygenation) in the pregnant or peripartum patient.


Eligibility criteria: Inclusion Criteria:

1. Female
2. Age 18 years or greater at the time of ECMO treatment.
3. Pregnant or within 6 months post-partum at the time of ECMO cannulation

Exclusion Criteria:

1. No history of pregnancy.
2. No treatment with ECMO.

Primary outcomes:
measure: Clinical Outcome of Mother
timeFrame: Time of diagnosis -Six Month Survival Rate
Secondary outcomes:
Other outcomes:
Locations:
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
Study officials:
affiliation: Medical College of Wisconsin
name: Sarah Thordsen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03802760: Cerebral Microembolism in Cardiology
Official title: Cerebral Microembolism in Interventional Cardiology Procedures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Embolism
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
First posted: 2019-01-14
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing Interventional cardiology procedure (TAVI, MitraClip, TricuspidalClip)

Brief summary: During different interventional cardiology procedures we aim to identify cerebral microemboli load. Further we aim to differentiate the quality and the quantity of cerebral microemboli.We will measure cerebral microemboli in different interventional phases, e.g. during valve deployment, rapid pacing, post-implantation.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Interventional cardiology procedure (TAVI, MitraClip, TricuspidalClip)

Exclusion Criteria:

* Allergy to ultrasound gel or materials contained in the TCD probe
* Missing temporal bone window

Primary outcomes:
measure: Quality of cerebral microemboli (solid vs. gaseous)
timeFrame: intraoperative phase, expected to be approx. 4 hours
Secondary outcomes:
measure: Quantity of cerebral microemboli load
timeFrame: intraoperative phase, expected to be approx. 4 hours
measure: Cerebral hemispheric differences (left vs. right)
timeFrame: intraoperative phase, expected to be approx. 4 hours
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Department of Anesthesiology and Pain Medicine
Study officials:
References: